Benzinga
14 Jul 2026, 18:33 UTC · 1h ago
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Benzinga
14 Jul 2026, 18:33 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Erasca reported a 57% unconfirmed objective response rate for ERAS-0015 in patients with second-line or later KRAS G12X pancreatic ductal adenocarcinoma at the 32 mg dose. — High response rates in hard-to-treat cancers like pancreatic ductal adenocarcinoma are strong positive clinical signals for oncology biotech valuation.
+0.80Erasca priced an upsized public offering of 31.4 million shares at $17.50, expected to generate approximately $550 million. — While offerings cause short-term dilution, the significant cash infusion reduces funding risk for the company's expensive upcoming pivotal trials.
+0.40The company plans to launch a registration-enabling trial in non-small cell lung cancer in H1 2027 and a Phase 3 trial in pancreatic ductal adenocarcinoma in 2027. — Clear timelines for pivotal trials provide a roadmap for potential commercialization and value inflection points.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
ERAS-0015 demonstrated a consistent safety profile with no dose-limiting toxicities and no discontinuations attributed to treatment-related adverse events. — A clean safety profile is necessary for FDA approval and minimizes the risk of trial failure due to toxicity.
+0.20Which stocks this story touches
Positive clinical data for cancer candidate ERAS-0015, an upsized public offering raising $550 million, and a significant share price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
4h ago
